Abstract
Real-world data is emerging as a source of data to evaluate drug effects that may provide unique benefits given the highly selected enrollment and participation of adult patients in clinical trials. This commentary considers the potential utility of real-world data in light of the recently reported results of the FLOWER study, which explore the safety and efficacy of osimertinib using a prospective single-arm design with real-world data sourced from clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
